In last trading session, Harvard Bioscience Inc (NASDAQ:HBIO) saw 1.43 million shares changing hands with its beta currently measuring 1.35. Company’s recent per share price level of $0.69 trading at -$0.07 or -10.10% at ring of the bell on the day assigns it a market valuation of $29.88M. That closing price of HBIO’s stock is at a discount of -581.16% from its 52-week high price of $4.70 and is indicating a discount of -10.14% from its 52-week low price of $0.76. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.36 million shares which gives us an average trading volume of 259.94K if we extend that period to 3-months.
For Harvard Bioscience Inc (HBIO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.01 in the current quarter.
Harvard Bioscience Inc (NASDAQ:HBIO) trade information
Upright in the red during last session for losing -10.10%, in the last five days HBIO remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $0.69 price level, adding 20.6% to its value on the day. Harvard Bioscience Inc’s shares saw a change of -67.54% in year-to-date performance and have moved -14.68% in past 5-day. Harvard Bioscience Inc (NASDAQ:HBIO) showed a performance of -51.42% in past 30-days. Number of shares sold short was 0.96 million shares which calculate 3.29 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 90.14% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 7. It follows that stock’s current price would drop -914.49% in reaching the projected high whereas dropping to the targeted low would mean a loss of -914.49% for stock’s current value.
Harvard Bioscience Inc (HBIO) estimates and forecasts
This year revenue growth is estimated to fall -1.68% from the last financial year’s standing.
2 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 20.95M for the same. And 2 analysts are in estimates of company making revenue of 22.65M in the next quarter. Company posted 24.51M and 23.1M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.80% during past 5 years.
Harvard Bioscience Inc (NASDAQ:HBIO)’s Major holders
Insiders are in possession of 7.22% of company’s total shares while institution are holding 80.49 percent of that, with stock having share float percentage of 86.75%. Investors also watch the number of corporate investors in a company very closely, which is 80.49% institutions for Harvard Bioscience Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HBIO for having 2.84 million shares of worth $8.1 million. And as of 2024-06-30, it was holding 6.5519 of the company’s outstanding shares.
The second largest institutional holder is PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC., which was holding about 2.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.3752 of outstanding shares, having a total worth of $7.9 million.
